The FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on nucleoside therapy, based on phase 3 trials showing 19% functional cure.
News|Articles|October 31, 2025
Pharmaceutical Executive Presents: Most Favored Nation Order - How Trump Is Disrupting Pharma
Author(s)PharmExec Staff
Listen
0:00 / 0:00
Key Takeaways
- The MFN model, DTC channels, and tariffs are set to transform drug market dynamics, affecting key stakeholders like payers and manufacturers.
- The webinar will evaluate if MFN is a sustainable reform or merely a political issue, impacting future healthcare policies.
Join us for a premium webinar on November 4, 2025!
Advertisement
With Most Favored Nation (MFN) and the emergence of the direct-to-consumer (DTC) model and potential tariffs, traditional roles of payers, pharmacy benefit managers, manufacturers, and 340B hospitals would be fundamentally reshaped.
Exploring the Impacts of MFN, Tariffs and DTC on Drug Markets
On November 4, this exclusive webinar will cut through the political noise and provide a critical, operational analysis of these seismic shifts. We will explore whether MFN is a foundation for permanent reform or simply a political flashpoint, how the proposed mandatory payment models GLOBE and GUARD fit into the future, and what the real-world impact of tariffs and DTC channels will be.
Advertisement
Related to this article
Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
FDA’s conditional approval of Jemperli (dostarlimab-gxly) rests on a single-arm phase 2 trial, with independent-review data still maturing.
Foundayo’s EU backing, Enspryng for TED, Gilead’s masked TCE deal, FDA’s rare disease reset, and Bausch + Lomb’s new interim CEO — explained.
Incubate’s John Stanford on why MFN deals are voluntary in name only — and why the leverage looks a lot like the IRA’s 95% excise tax.
Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
The interleukin-6 receptor inhibitor gains a second indication, though one of two phase 3 trials missed its primary endpoint.
Advertisement
Advertisement
Trending on PharmExec
1
CSL Names Deborah Waterhouse as CEO and Manager Director
2
The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals
3
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
4
METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies
5